Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DALGAN vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Management of moderate to severe pain (FDA-approved),Preoperative analgesia,Postoperative pain relief,Adjunct to anesthesia
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal half-life: 2–3 hours; clinically may be prolonged in renal impairment.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily hepatic via glucuronidation and N-demethylation. Involves UDP-glucuronosyltransferase (UGT) enzymes and possibly cytochrome P450 (CYP) 3A4 contributes to minor metabolism to inactive metabolites.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal: ~90% as unchanged drug and glucuronide conjugates; biliary/fecal: ~10%.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
~20% bound to albumin and alpha-1-acid glycoprotein.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
3–5 L/kg; suggests extensive tissue distribution.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 40–60% (first-pass metabolism); IM: ~70%; rectal: ~50%.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
GFR 10-50 m L/min: administer 50-75% of usual dose every 8-12 hours. GFR <10 m L/min: administer 50% of usual dose every 12 hours.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% and extend interval to every 8-12 hours. Child-Pugh C: reduce dose by 75% and extend interval to every 12 hours.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Oral: 0.5-1 mg/kg every 4-6 hours; maximum 4 mg/kg/day. IV: 0.3-0.5 mg/kg every 6 hours; maximum 2 mg/kg/day.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Initiate at 50% of adult dose; titrate slowly to response; maximum 300 mg/day. Avoid in patients with creatinine clearance <30 m L/min.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS. Dalgan exposes users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Serious, life-threatening, or fatal respiratory depression may occur. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Life-threatening respiratory depression: monitor closely, especially during initiation or dose escalation,Opioid-induced hyperalgesia: paradoxical increase in pain sensitivity,Adrenal insufficiency: monitor for symptoms of hypocortisolism,Severe hypotension: risk in hypovolemic patients or those with compromised blood pressure,Seizures: may exacerbate seizure disorders,Risks of use in patients with head injury or increased intracranial pressure,Avoid abrupt discontinuation: taper dose to prevent withdrawal syndrome,May precipitate withdrawal in opioid-dependent patients due to antagonist activity at mu receptors
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to dezocine or any component of the formulation,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid grapefruit juice as it may increase dezocine levels via CYP3A4 inhibition. No other significant food interactions reported; take with or without food. Limit alcohol to prevent additive CNS depression.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
FDA Pregnancy Category C: First trimester risk of major malformations unknown; animal studies show fetal toxicity at high doses. Second/third trimester: risk of neonatal withdrawal syndrome if prolonged use near term. Avoid unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Excreted in breast milk; M/P ratio not established. Limited human data; potential for infant sedation and withdrawal. Use only if essential, monitor infant for drowsiness and poor feeding.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No standard dose adjustments; pharmacokinetic changes (increased clearance, volume of distribution) may require higher doses to maintain efficacy. Use lowest effective dose; avoid in first trimester if possible. Taper to prevent withdrawal.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Dalgan (dezocine) is a mixed agonist-antagonist opioid with ceiling effect for respiratory depression; use caution in opioid-tolerant patients due to risk of precipitating withdrawal. Not recommended for prolonged use due to potential for dependence. Monitor for hypotension and bradycardia, especially in elderly or volume-depleted patients.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid driving or operating heavy machinery until you know how this medication affects you.,Do not consume alcohol or other central nervous system depressants while taking this drug.,Report any signs of withdrawal (e.g., anxiety, sweating, cramping) or allergic reaction (rash, difficulty breathing) immediately.,Store at room temperature away from moisture and heat; keep out of reach of children.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DALGAN vs ACTIQ, answered by our medical review team.
DALGAN is a Opioid Analgesic that works by Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DALGAN and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DALGAN is: Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DALGAN and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DALGAN is classified as Category C. FDA Pregnancy Category C: First trimester risk of major malformations unknown; animal studies show fetal toxicity at high doses. Second/third trimester: risk of neonatal withdrawal. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.